PriceTargets.com logo

GH Research - GHRS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.67
  • Forecasted Upside: 420.68%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.85 As of 12/20/2024 06:51 PM ET
▼ -0.54 (-7.31%)

This chart shows the closing price for GHRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GH Research Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GHRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GHRS

Analyst Price Target is $35.67
▲ +420.68% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GH Research in the last 3 months. The average price target is $35.67, with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 420.68% upside from the last price of $6.85.

This chart shows the closing price for GHRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in GH Research. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
11/18/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$31.00 ➝ $28.00
9/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
9/4/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$39.00 ➝ $39.00
7/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00
5/6/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$30.00 ➝ $31.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00
3/1/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $39.00
1/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$40.00
11/14/2023HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $40.00
5/12/2023JMP SecuritiesBoost Target$46.00 ➝ $49.00
3/13/2023HC WainwrightReiterated RatingBuy$45.00
3/2/2023EF Hutton Acquisition Co. IReiterated RatingBuy$33.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$33.00
12/15/2022UBS GroupInitiated CoverageBuy
8/16/2022HC WainwrightInitiated CoverageBuy$45.00
6/15/2022Roth CapitalInitiated CoverageBuy$66.00
4/13/2022Canaccord Genuity GroupLower TargetBuy$45.00 ➝ $41.00
9/24/2021JMP SecuritiesReiterated RatingBuy$36.00
7/20/2021CowenInitiated CoverageOutperform$17.25
7/20/2021Stifel NicolausInitiated CoverageBuy$26.00
7/20/2021JMP SecuritiesInitiated CoverageOutperform$35.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

GH Research logo
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $6.85
Low: $6.72
High: $7.63

50 Day Range

MA: $8.43
Low: $6.85
High: $10.95

52 Week Range

Now: $6.85
Low: $5.08
High: $14.99

Volume

76,470 shs

Average Volume

78,083 shs

Market Capitalization

$356.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of GH Research?

The following equities research analysts have issued reports on GH Research in the last twelve months: Canaccord Genuity Group Inc., HC Wainwright, and JMP Securities.
View the latest analyst ratings for GHRS.

What is the current price target for GH Research?

0 Wall Street analysts have set twelve-month price targets for GH Research in the last year. Their average twelve-month price target is $35.67, suggesting a possible upside of 420.7%. HC Wainwright has the highest price target set, predicting GHRS will reach $40.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $28.00 for GH Research in the next year.
View the latest price targets for GHRS.

What is the current consensus analyst rating for GH Research?

GH Research currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GHRS will outperform the market and that investors should add to their positions of GH Research.
View the latest ratings for GHRS.

What other companies compete with GH Research?

Other companies that are similar to GH Research include Evotec, Arcutis Biotherapeutics, Arcus Biosciences, Nurix Therapeutics and Kiniksa Pharmaceuticals. Learn More about companies similar to GH Research.

How do I contact GH Research's investor relations team?

The company's listed phone number is 212-450-4000 and its investor relations email address is [email protected]. The official website for GH Research is www.ghres.com. Learn More about contacing GH Research investor relations.